Fasken advised Mackie Research Capital Corporation on the deal.
Algernon Pharmaceuticals Inc. closed its placement offering of special warrants of the Company, which included the exercise of the over-allotment option, pursuant to which the Company issued 19,605,285 Special Warrants at a price of $0.35 per Special Warrant, for aggregate gross proceeds of approximately $6,861,849.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
The offering was led by Mackie Research Capital Corporation, as sole agent and bookrunner.
The Fasken team consisted of John Sabetti (Picture), Zach Austin, Taisha Lewis and Mitchell Thaw.
Law Firms: Fasken Martineau;
Clients: Mackie Research Capital Corporation;